All News

playbook2 ACR

Check Out the Virtual ACR Playbook

d Jack Cush, MD

If you need a plan for this weekend's ACR meeting, check out and download our latest, "Virtual ACR 2020 Playbook". The playbook covers: setting virtual learning goals, sessions you probably shouldn't miss, how to still have peer interactions, what to do if you only have time to "dabble' - and more.

Read Article
infx.pneumonia.jpg

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months

d Jack Cush, MD

The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 

Read Article
RN.Laptop.jpg

ACR 2020 Your Way - Get Your Topic Emails

d Jack Cush, MD

ACR is but a few days away; the question is: how will you tackle this virtual meeting? RheumNow has created several options for learning the way you want to. First is to feed your need. Are you a lupologist? A gout maven? A Spondylitis sleuth? A drug safety wannabe?

Read Article
PSA%20026.jpg

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

d Jack Cush, MD

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 

Read Article
SPA.spectrum.jpg

SPARTAN ACR20 Recommendations on Spondyloarthritis

d Jack Cush, MD

SPARTAN has compiled a list of presentations and sessions worth seeing if you are interested in ankylosing spondylitis, spondyloarthritis and related disorders.

Read Article
moneyglobe.jpg

US Differs from Worldwide Drug Reimbursements

d Jack Cush, MD

"The US has nearly 4.5% of the world’s population but accounts for more than 40% of global drug spending" reports JAMA Internal Medicine.  US drug prices are nearly double those of Australia, Canada, and the United Kingdom, and the US spends twice as much on retail and nonretai

Read Article
Check out our "Virtual ACR2020 Playbook" to plan how you will take in and consume ACR20 from home and in your fuzzy slippers. https://t.co/5bsOFFXEMZ

Links:

Dr. John Cush RheumNow ( View Tweet)

#LTF Please wear your mask https://t.co/dzN0SDLb0T
Dr. John Cush RheumNow ( View Tweet)
Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zoledronate (0.62), calcium were negatively associated with COVID-19. Why? is it that they are less "sick"? https://t.co/BNbwsCz0rA

Links:

Dr. John Cush RheumNow ( View Tweet)

Eosinophilia in #RA is either due to a secondary problem (endemic parasitosis, drug hypersensitivity, etc) or may be associated with more severe RA - it is not associated with extraarticular manifestations of RA. https://t.co/J9rOA3cWC4

Links:

Dr. John Cush RheumNow ( View Tweet)

Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG

Links:

Dr. John Cush RheumNow ( View Tweet)

Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM

Links:

Dr. John Cush RheumNow ( View Tweet)

Cohort study (n 186) from NYC shows that patients with COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressives https://t.co/TMCcKbns0f

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of the literatures (19 studies, 241 138 participants) shows ibuprofen vs acetaminophen for fever or pain in children <2 years was associated with equivalent safety and improved temperature and pain within the first 24 hours https://t.co/4y5dww22Gw

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 55 SpA patients with axial disease. 31% had high risk of falls (by survey) and 25% recalled having at least one fall in the last years. Risk higher w/ activity and adv disease. Pts w/ falls had lower quality of life. https://t.co/yu6mP6sxth

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis https://t.co/I2dzetdgBw

Links:

Dr. John Cush RheumNow ( View Tweet)

Lowest Specialty Salaries in 2020 Preventive med: $234K Pediatrics: $243K Medical genetics: $252K Endocrine: $259K Family med: $261K Geriatrics: $272K Infectious dz: $277K Internal med: $280K Rheumatology: $289K Occupational med: $293K Rheum! we are #9 https://t.co/zEs8WxVgG9

Links:

Dr. John Cush RheumNow ( View Tweet)

Exciting to hear about 5 trials for #GCA 1. ABAGART (#Abatacept) 2. METOGIA (#tocilizumab vs MTX) 3. SELECT (#upadacitinib) 4. MAVRILIMUMAB (#gmcsf i) 5. TiTIAN (#secukinumab) ⁦@VasculitisFound⁩ #vasculitis #vcrc https://t.co/DVvG5Ekfu9
KenWarringtonMD MdWarrington ( View Tweet)
Did you see the results of our "Are Rheums Attending ACR 2020?" Survey. 41% will attend live 23% will learn off hours 2/3 are registered for ACR 20% just won't go 37% are taking time off to attend See ou recs on how to learn based on where you fit above https://t.co/K4qHSJ07P2

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×